Scinovex
articleTop 1% cited

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)

Drugs · 2004 · Vol. 64(Supplement 2) · pp. 43–60
Peter SeverBj??rn Dahl??fNeil R PoulterHans WedelGareth BeeversMark J. CaulfieldRory CollinsSverre E. KjeldsenArni KristinssonGordon T. McInnesJesper MehlsenMarkku S. NieminenEoin OʼBrienJan stergren
Lipoproteins and Cardiovascular HealthBlood Pressure and Hypertension StudiesPharmaceutical Economics and PolicyMedicineAtorvastatinHazard ratioMyocardial infarctionInternal medicineStroke (engine)PlaceboClinical endpointCardiologyCholesterol

MeSH terms

AtorvastatinAdultAgedCholesterolCoronary DiseaseFemaleUnited KingdomHeptanoic AcidsHumansHypertensionMaleMiddle AgedMyocardial InfarctionPyrrolesScandinavian and Nordic Countries

Funding

  • Sahlgrenska Universitetssjukhuset
  • Servier
Citations
523
FWCI
70.98
field-weighted impact
References
42
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA) · Scinovex